Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Oral NNC0385-0434 in Healthy Japanese Men
NCT05003440Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2021
- Primary completion
- Jan 2022
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NNC0385-0434 in hypercholesterolemia (6 arms), sponsored by Novo Nordisk. Primary endpoint: Treatment Emergent Adverse Events. Started Aug 2021; status: completed.
02
Drugs
NNC0385-0434
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05003440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05003440.